{"id":{"repo_id":"marshall","oai_identifier":"oai:mds.marshall.edu:etd-2714"},"canonical_url":"https://search.ndltd.org/etd/marshall/oai:mds.marshall.edu:etd-2714","repository":{"repo_id":"marshall","name":"Marshall University","base_url":"https://mds.marshall.edu/do/oai/"},"display":{"title":"Costs and length of stay associated with treating Neonatal Abstinence Syndrome","abstract":"Introduction: Neonatal Abstinence Syndrome has been costly for the healthcare system, for every 19 minutes a baby was diagnosed in 2021. Costs and Length of Stay both had been increased for newborns diagnosed. Medically Assisted Treatment for expecting mothers has shown to decrease costs and length of stay for newborns with neonatal abstinence syndrome. Methodology: This study utilized a literature review and a semi-structured interview. Three databases were used to collect 126 total sources. These sources were reviewed and reduced to 30 total sources that were used in the written research. Of these, 14 sources were used in the results section. Purpose of the Study: The purpose of this research was to analyze the difference between cost and length of stay for newborns with Neonatal Abstinence Syndrome between mothers who participated in Medication Assisted Treatment (MAT) and those who were in active substance use up to the time of birth with MAT. Results: The research showed that medically assisted treatment with methadone or buprenorphine during pregnancy decreased costs, length of stay, and severity of symptoms for newborns diagnosed with NAS. Barriers are still present for expectant mothers wanting to receive MAT intervention. Discussion/Conclusion: Medication Assisted Treatment (MAT) during pregnancy has been shown to have a positive correlation with a shorter initial length of stay for infants with Neonatal Abstinence Syndrome (NAS). The findings show a positive correlation with lower costs for the initial stay of infants whose mother received MAT.","abstract_html":"Introduction: Neonatal Abstinence Syndrome has been costly for the healthcare system, for every 19 minutes a baby was diagnosed in 2021. Costs and Length of Stay both had been increased for newborns diagnosed. Medically Assisted Treatment for expecting mothers has shown to decrease costs and length of stay for newborns with neonatal abstinence syndrome. Methodology: This study utilized a literature review and a semi-structured interview. Three databases were used to collect 126 total sources. These sources were reviewed and reduced to 30 total sources that were used in the written research. Of these, 14 sources were used in the results section. Purpose of the Study: The purpose of this research was to analyze the difference between cost and length of stay for newborns with Neonatal Abstinence Syndrome between mothers who participated in Medication Assisted Treatment (MAT) and those who were in active substance use up to the time of birth with MAT. Results: The research showed that medically assisted treatment with methadone or buprenorphine during pregnancy decreased costs, length of stay, and severity of symptoms for newborns diagnosed with NAS. Barriers are still present for expectant mothers wanting to receive MAT intervention. Discussion/Conclusion: Medication Assisted Treatment (MAT) during pregnancy has been shown to have a positive correlation with a shorter initial length of stay for infants with Neonatal Abstinence Syndrome (NAS). The findings show a positive correlation with lower costs for the initial stay of infants whose mother received MAT.","abstract_has_math":false,"creators":["Stanfield, Kimberly","Day, Kylie"],"institution":null,"degree_name":"Healthcare Administration","degree_level":"Research Paper","degree_discipline":"College of Business","degree_department":null,"school":null,"contributors":["Alberto Coustasse"],"advisors":[],"committee_chairs":[],"committee_members":[],"year":null,"date_issued":"","date_published":null,"updated_at":"2026-11-21T19:57:51Z","subjects":["Business","Business Administration, Management, and Operations","Health and Medical Administration","Medicine and Health Sciences","Cost","Medically Assisted Treatment","MAT Intervention","Neonatal Abstinence Syndrome","Substance Use Disorder"],"languages":[],"rights":[],"rights_urls":[],"identifier_entries":[],"person_identifier_entries":[]},"links":{"outbound_url":"https://mds.marshall.edu/etd/1709","outbound_label":"Repository record","outbound_source":"dc:identifier","record_url":"https://mds.marshall.edu/etd/1709","record_label":"Repository record","record_kind":"record","record_source":"dc:identifier","download_url":null,"download_label":null,"download_source":null,"access_status":null,"embargo_until":null,"access_note":null},"source_record":{"url":"https://mds.marshall.edu/do/oai/?verb=GetRecord&metadataPrefix=oai_etdms&identifier=oai%3Amds.marshall.edu%3Aetd-2714","prefix":"oai_etdms"},"metadata_groups":[{"id":"people","label":"People","entries":[{"key":"dc:contributor","label":"Contributor","values":["Alberto Coustasse"]},{"key":"dc:creator","label":"Author","values":["Stanfield, Kimberly","Day, Kylie"]}]},{"id":"academic_context","label":"Academic Context","entries":[{"key":"dc:date.available","label":"Dc Date Available","values":["2023-02-21T08:00:00Z"]},{"key":"dc:date.created","label":"Dc Date Created","values":["2022-01-01T08:00:00Z"]},{"key":"thesis:degree_discipline","label":"Discipline","values":["College of Business"]},{"key":"thesis:degree_level","label":"Degree Level","values":["Research Paper"]},{"key":"thesis:degree_name","label":"Degree Name","values":["Healthcare Administration"]}]},{"id":"subjects_keywords","label":"Subjects and Keywords","entries":[{"key":"dc:subject","label":"Dc Subject","values":["Business","Business Administration, Management, and Operations","Health and Medical Administration","Medicine and Health Sciences","Cost","Medically Assisted Treatment","MAT Intervention","Neonatal Abstinence Syndrome","Substance Use Disorder"]}]},{"id":"identifiers","label":"Identifiers","entries":[{"key":"dc:identifier","label":"Identifier","values":["https://mds.marshall.edu/etd/1709"]}]},{"id":"additional","label":"Additional Metadata","entries":[{"key":"dc:description.abstract","label":"Abstract","values":["Introduction: Neonatal Abstinence Syndrome has been costly for the healthcare system, for every 19 minutes a baby was diagnosed in 2021. Costs and Length of Stay both had been increased for newborns diagnosed. Medically Assisted Treatment for expecting mothers has shown to decrease costs and length of stay for newborns with neonatal abstinence syndrome. Methodology: This study utilized a literature review and a semi-structured interview. Three databases were used to collect 126 total sources. These sources were reviewed and reduced to 30 total sources that were used in the written research. Of these, 14 sources were used in the results section. Purpose of the Study: The purpose of this research was to analyze the difference between cost and length of stay for newborns with Neonatal Abstinence Syndrome between mothers who participated in Medication Assisted Treatment (MAT) and those who were in active substance use up to the time of birth with MAT. Results: The research showed that medically assisted treatment with methadone or buprenorphine during pregnancy decreased costs, length of stay, and severity of symptoms for newborns diagnosed with NAS. Barriers are still present for expectant mothers wanting to receive MAT intervention. Discussion/Conclusion: Medication Assisted Treatment (MAT) during pregnancy has been shown to have a positive correlation with a shorter initial length of stay for infants with Neonatal Abstinence Syndrome (NAS). The findings show a positive correlation with lower costs for the initial stay of infants whose mother received MAT."]},{"key":"dc:title","label":"Title","values":["Costs and length of stay associated with treating Neonatal Abstinence Syndrome"]}]}],"canonical_facts":{"dc:contributor":["Alberto Coustasse"],"dc:creator":["Stanfield, Kimberly","Day, Kylie"],"dc:date.available":["2023-02-21T08:00:00Z"],"dc:date.created":["2022-01-01T08:00:00Z"],"dc:description.abstract":["Introduction: Neonatal Abstinence Syndrome has been costly for the healthcare system, for every 19 minutes a baby was diagnosed in 2021. Costs and Length of Stay both had been increased for newborns diagnosed. Medically Assisted Treatment for expecting mothers has shown to decrease costs and length of stay for newborns with neonatal abstinence syndrome. Methodology: This study utilized a literature review and a semi-structured interview. Three databases were used to collect 126 total sources. These sources were reviewed and reduced to 30 total sources that were used in the written research. Of these, 14 sources were used in the results section. Purpose of the Study: The purpose of this research was to analyze the difference between cost and length of stay for newborns with Neonatal Abstinence Syndrome between mothers who participated in Medication Assisted Treatment (MAT) and those who were in active substance use up to the time of birth with MAT. Results: The research showed that medically assisted treatment with methadone or buprenorphine during pregnancy decreased costs, length of stay, and severity of symptoms for newborns diagnosed with NAS. Barriers are still present for expectant mothers wanting to receive MAT intervention. Discussion/Conclusion: Medication Assisted Treatment (MAT) during pregnancy has been shown to have a positive correlation with a shorter initial length of stay for infants with Neonatal Abstinence Syndrome (NAS). The findings show a positive correlation with lower costs for the initial stay of infants whose mother received MAT."],"dc:identifier":["https://mds.marshall.edu/etd/1709"],"dc:subject":["Business","Business Administration, Management, and Operations","Health and Medical Administration","Medicine and Health Sciences","Cost","Medically Assisted Treatment","MAT Intervention","Neonatal Abstinence Syndrome","Substance Use Disorder"],"dc:title":["Costs and length of stay associated with treating Neonatal Abstinence Syndrome"],"thesis:degree_discipline":["College of Business"],"thesis:degree_level":["Research Paper"],"thesis:degree_name":["Healthcare Administration"]},"updated_at":"2026-11-21T19:57:51Z"}